CD73 is associated with poor prognosis in high-grade serous ovarian cancer.

@article{Turcotte2015CD73IA,
  title={CD73 is associated with poor prognosis in high-grade serous ovarian cancer.},
  author={Martin Turcotte and Kathleen Spring and Sandra A Pommey and Guillaume Chouinard and Isabelle Cousineau and Joshy George and Gregory M. Chen and Deena M A Gendoo and Benjamin Haibe-Kains and Thomas Karn and Kurosh Rahimi and C{\'e}cile Le Page and Diane Mich{\`e}le Provencher and Anne-Marie Mes-Masson and J. P. Stagg},
  journal={Cancer research},
  year={2015},
  volume={75 21},
  pages={4494-503}
}
The cell surface nucleotidase CD73 is an immunosuppressive enzyme involved in tumor progression and metastasis. Although preclinical studies suggest that CD73 can be targeted for cancer treatment, the clinical impact of CD73 in ovarian cancer remains unclear. In this study, we investigated the prognostic value of CD73 in high-grade serous (HGS) ovarian cancer using gene and protein expression analyses. Our results demonstrate that high levels of CD73 are significantly associated with shorter… CONTINUE READING